AI Article Synopsis
- Dimethoxytolyl propylresorcinol (UP302) is a natural compound with tyrosinase inhibitory and antioxidant properties, commonly used in skin-whitening cosmetics, but its effects on cancer treatment were previously unexamined.
- This study demonstrated that UP302 can inhibit the growth of leukemia cells, inducing apoptosis and promoting autophagy, especially in cell lines MV411 and K562.
- The research suggests potential for using UP302 in combination with autophagy inhibitors as a new strategy for treating human leukemia.
Article Abstract
Dimethoxytolyl propylresorcinol (UP302), a natural compound extracted from owing to its tyrosinase inhibitory and strong antioxidant properties, is used in whitening cosmetics. However, the role of UP302 has not been reported in cancer treatment. This study aimed to assess the antitumor activity of UP302 in different tumor cells. It inhibited the growth of certain cancer cell lines and especially in leukemia cells. Therefore, we investigated the antitumor effect of UP302 in leukemia by examining the cell cycle, apoptosis, reactive oxygen species levels (ROS) production, and changes in mitochondrial membrane potential. Our results demonstrated that UP302 inhibited the growth of leukemia cells both and and exerted a proapoptotic effect on MV411 and K562 cells, confirmed by flow cytometry and western blot analysis. Furthermore, UP302 promoted autophagy in MV411 and K562 cells. Transmission electron microscopy and western blot analysis showed that UP302 induced mitophagy in MV411 and K562 cells. In addition, the autophagy inhibitor chloroquine could enhance UP302-induced apoptosis, suggesting that UP302-mediated autophagy may be protective in MV411 and K562 cells. In conclusion, our study is the first to provide evidence for the anti-leukemia properties of UP302 and the potential clinical use of UP302 combined with autophagy inhibitors as a chemotherapeutic strategy for human leukemia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751666 | PMC |
| http://dx.doi.org/10.7150/jca.89243 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlabelled: Hematological cancer treatment with hybrid kinase/HDAC inhibitors is a novel strategy to overcome the challenge of acquired resistance to drugs. We collected IC datasets from the ChEMBL database for 13 cancer cell lines (72 h cytotoxicity, measured by MTT), known inhibitors for 38 kinases, and 10 HDACs isoforms, that we identified by target fishing and literature review. The data was subjected to rigorous biological and chemical curation leaving the final datasets ranging from 76 to 8173 compounds depending on the target.
View Article and Find Full Text PDFIdentification of furo[2,3-d]pyrimidin-4-ylsulfanyl-1,3,4-thiadiazole derivatives as novel FLT3-ITD inhibitors.
Eur J Med Chem
December 2024
Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Given the significant prevalence of FLT3 receptor and its mutations in acute myeloid leukemia (AML) pathogenesis, we present a novel series of furo[2,3-d]pyrimidin-1,3,4-thiadiazole-urea derivatives, designed to exhibit FLT3-ITD inhibitory activity. These compounds demonstrated cytotoxicity in FLT3-ITD expressing AML cell lines MOLM-13 and MV4-11 in the nanomolar range, with significant selectivity over the K562 cell line. In-depth evaluations of example compound 49 revealed its efficacy in suppressing FLT3 phosphorylation and the downstream signaling molecules, including STAT5 and ERK1/2.
View Article and Find Full Text PDFDesign, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents.
Bioorg Chem
December 2024
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan. Electronic address:
Disruptor of telomeric silencing 1-like (DOT1L) is a key hub in histone lysine methyltransferase and an attractive therapeutic target for treating hematological malignancies including acute myeloid leukemia (AML). In this study, we report the design and synthesis of a new series of adenosine derivatives as DOT1L inhibitors by accommodating a basic linker piperidine-4-ylmethyl motif to respective aryl-urea/benzimidazole scaffolds. The anti-DOT1L enzyme activity analysis demonstrated that compounds 8, 12, and 13 strongly suppressed DOT1L activity with IC values ranging from 0.
View Article and Find Full Text PDFRenin-Angiotensin System Inhibitors Suppress the Growth of Leukemia Cells.
Anticancer Res
March 2024
Department of Laboratory Medicine, Tokyo Medical and Dental University (TMDU), Tokyo, Japan;
Background/aim: The renin-angiotensin system (RAS) regulates blood pressure. The RAS is also related to cell growth, and its activation has been reported in various cancer cells. Therefore, we investigated the effects of RAS inhibitors on the in vitro growth of leukemia cell lines.
View Article and Find Full Text PDFDimethoxytolyl propylresorcinol induces apoptosis and mitophagy in human leukemia cells through the PI3K/AKT pathway.
J Cancer
January 2024
Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Article Synopsis
- Dimethoxytolyl propylresorcinol (UP302) is a natural compound with tyrosinase inhibitory and antioxidant properties, commonly used in skin-whitening cosmetics, but its effects on cancer treatment were previously unexamined.
- This study demonstrated that UP302 can inhibit the growth of leukemia cells, inducing apoptosis and promoting autophagy, especially in cell lines MV411 and K562.
- The research suggests potential for using UP302 in combination with autophagy inhibitors as a new strategy for treating human leukemia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!